ESAs, such as recombinant human EPO (epoetin alfa or rHuEPO) and its hyperglycosylated derivative darbepoetin alfa, are standard-of-care therapies for the treatment of anemia associated with CKD. Here, EPO is linked to chronic kidney disease.